Search

CN-121995062-A - Biomarker combination for cervical cancer molecular subtype identification, kit and application

CN121995062ACN 121995062 ACN121995062 ACN 121995062ACN-121995062-A

Abstract

The invention relates to the technical field of medical detection, and particularly discloses a biomarker combination, a kit and application for cervical cancer molecular subtype identification. The biomarker combination comprises protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1, and molecular subtype related analysis is carried out on a sample by detecting the relative expression characteristics of the proteins in a cervical cancer in-vitro sample. Cervical cancer samples can be classified into at least one of an epithelial-mesenchymal transition-related subtype, a proliferation-related subtype, an immune response-related subtype, and an epithelial differentiation-related subtype based on the relative expression characteristics of the respective proteins. The invention also provides a detection kit and an analysis system for realizing cervical cancer molecular subtype identification. The technical scheme can carry out molecular typing on cervical cancer from the protein function execution level, provides a reliable technical means for molecular typing research, prognosis evaluation and accurate treatment related research of cervical cancer, and has good application prospect.

Inventors

  • TIAN XUN
  • ZHANG QINGHUA
  • WANG ZHI
  • FANG TIAN
  • WU YIFAN

Assignees

  • 武汉市中心医院（武汉市第二医院、武汉市肿瘤研究所）

Dates

Publication Date
20260508
Application Date
20260206

Claims (10)

  1. 1. A biomarker combination for cervical cancer molecular subtype identification, characterized in that the biomarker combination comprises protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1, and the biomarker combination performs molecular subtype related analysis on cervical cancer samples through the relative expression characteristics of protein CDH13, protein TP53BP1, protein NNMT and protein HSPB 1.
  2. 2. The biomarker combination according to claim 1, wherein the molecular subtype-related analysis is performed based on a synergistic or differential expression pattern of the proteins CDH13, TP53BP1, NNMT and HSPB1 in a sample.
  3. 3. The biomarker combination according to any of claims 1 or 2, wherein the protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1 are present as protein bodies, antibodies, antigen binding fragments or detectable forms thereof, respectively.
  4. 4. The biomarker combination according to any of claims 1 or 2, wherein the molecular subtypes include at least four of the following: epithelial-mesenchymal transition-related subtypes, proliferation-related subtypes, immune response-related subtypes and epithelial differentiation-related subtypes.
  5. 5. Use of a biomarker combination according to any of claims 1 or 2 in the manufacture of a product for cervical cancer molecular subtype analysis.
  6. 6. A kit for cervical cancer molecular subtype analysis, characterized in that the kit comprises a biomarker combination according to any of claims 1 to 3, and at least one detection reagent for detecting the biomarker.
  7. 7. The kit of claim 5, wherein the detection reagent comprises at least one of a labeled antibody, a chromogenic substrate, or a buffer.
  8. 8. A method for identifying a cervical cancer molecular subtype for non-clinical diagnostic purposes, comprising the steps of: Obtaining an in-vitro sample of cervical cancer to be detected; detecting the expression levels of protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1 in the sample; and performing molecular subtype correlation analysis on the isolated sample based on the relative expression characteristics among the protein CDH13, the protein TP53BP1, the protein NNMT and the protein HSPB 1.
  9. 9. The method of claim 8, wherein the molecular subtype-related analysis includes classifying the sample into at least one of an epithelial-mesenchymal transition-related subtype, a proliferation-related subtype, an immune response-related subtype, or an epithelial differentiation-related subtype.
  10. 10. An assay system for cervical cancer molecular subtype analysis, comprising: The data acquisition module is used for acquiring the original data of the expression levels of the protein CDH13, the protein TP53BP1, the protein NNMT and the protein HSPB 1; a computing module for processing the raw data to extract a relative expression feature; and the classification module is used for outputting corresponding molecular subtype classification and prognosis prediction results based on the relative expression characteristics.

Description

Biomarker combination for cervical cancer molecular subtype identification, kit and application Technical Field The invention relates to the technical field of medical detection, in particular to a biomarker combination for identifying cervical cancer molecular subtypes, a kit and application. Background Cervical cancer is one of the most common malignant tumors of women worldwide, and the onset of cervical cancer is closely related to persistent infection of high-risk human papillomaviruses. Although human papillomavirus screening has been widely popularized, current clinical treatment strategies (including surgery, radiotherapy and chemotherapy and targeted therapy) have limited effects on advanced, recurrent or metastatic patients, and five-year survival rates wander at lower levels for a long period of time, highlighting the obvious limitations of the "one-knife" treatment mode under traditional pathological typing guidance. In recent years, with the breakthrough of high throughput sequencing and multiple-mathematics, cancer research has entered the molecular typing era. In the fields of endometrial cancer, breast cancer, colorectal cancer and the like, molecular typing systems based on genome, transcriptome and proteome have successfully led to clinical prognosis evaluation and accurate treatment decisions. However, the molecular typing research of cervical cancer is relatively lagged, and clinical diagnosis and treatment decisions are still mainly carried out according to pathological forms (such as squamous cell carcinoma and adenocarcinoma) and FIGO stages, so that the inherent biological heterogeneity of tumors is not fully reflected. This heterogeneity directly leads to significant differences in response and prognosis for the same pathological type, same stage patients to treatment. Therefore, there is a need to provide a simple, rapid and cost-effective cervical cancer molecular typing solution. How to screen the molecular parting biomarker combination with high sensitivity and high specificity, and select and implement an effective, stable and repeatable quantitative detection scheme to realize reliable differentiation of cervical cancer molecular subtypes is a key technical problem to be solved in clinic. Disclosure of Invention The object of the present invention is to address the above-mentioned deficiencies of the prior art by providing a biomarker combination, kit and use for cervical cancer molecular subtype identification comprising four proteins CDH13, TP53BP1, NNMT and HSPB1, capable of identifying four molecular subtypes with significantly different clinical prognosis, epithelial-mesenchymal transition (EMT, C1), proliferation (C2), immune response (C3) and epithelial differentiation (C4). In order to achieve the above purpose, the present invention adopts the following technical scheme: in a first aspect, the present invention provides a biomarker combination for cervical cancer molecular subtype identification, comprising protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1, wherein the biomarker combination performs molecular subtype related analysis on cervical cancer samples by means of the relative expression profile of protein CDH13, protein TP53BP1, protein NNMT and protein HSPB 1. Further, the molecular subtype-related analysis is performed based on a synergistic or differential expression pattern of the protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1 in the sample. Further, the protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1 are present as protein bodies, antibodies, antigen binding fragments or detectable forms thereof, respectively. Further, the molecular subtypes include at least the following four types: epithelial-mesenchymal transition-related subtypes, proliferation-related subtypes, immune response-related subtypes and epithelial differentiation-related subtypes. In a second aspect, the invention provides the use of said biomarker combination for the manufacture of a product for cervical cancer molecular subtype analysis. In a third aspect, the present invention provides a kit for cervical cancer molecular subtype identification detection, said kit comprising said biomarker combination and at least one detection reagent for detecting said biomarker. Further, the detection reagent includes at least one of a labeled antibody, a chromogenic substrate, or a buffer. In a fourth aspect, the present invention provides a method for identifying a cervical cancer molecular subtype for non-clinical diagnostic purposes, comprising the steps of: Obtaining an in-vitro sample of cervical cancer to be detected; detecting the expression levels of protein CDH13, protein TP53BP1, protein NNMT and protein HSPB1 in the sample; and performing molecular subtype correlation analysis on the isolated sample based on the relative expression characteristics among the protein CDH13, the protein TP53BP1, the protein NNMT and the protein HSPB 1. Further, the